[go: up one dir, main page]

DK2066695T3 - Anti-myostatin-antistoffer - Google Patents

Anti-myostatin-antistoffer

Info

Publication number
DK2066695T3
DK2066695T3 DK07841245.9T DK07841245T DK2066695T3 DK 2066695 T3 DK2066695 T3 DK 2066695T3 DK 07841245 T DK07841245 T DK 07841245T DK 2066695 T3 DK2066695 T3 DK 2066695T3
Authority
DK
Denmark
Prior art keywords
myostatin antibodies
myostatin
antibodies
Prior art date
Application number
DK07841245.9T
Other languages
English (en)
Inventor
Lihua Huang
Robert Owen Sayers
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2066695T3 publication Critical patent/DK2066695T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK07841245.9T 2006-09-05 2007-08-23 Anti-myostatin-antistoffer DK2066695T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82449806P 2006-09-05 2006-09-05
PCT/US2007/076604 WO2008030706A2 (en) 2006-09-05 2007-08-23 Anti-myostatin antibodies

Publications (1)

Publication Number Publication Date
DK2066695T3 true DK2066695T3 (da) 2013-06-10

Family

ID=39047560

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07841245.9T DK2066695T3 (da) 2006-09-05 2007-08-23 Anti-myostatin-antistoffer

Country Status (21)

Country Link
US (1) US8063188B2 (da)
EP (1) EP2066695B1 (da)
JP (1) JP5058261B2 (da)
KR (1) KR101123531B1 (da)
CN (1) CN101511871B (da)
AU (1) AU2007292555B2 (da)
BR (1) BRPI0716249A2 (da)
CA (1) CA2661836A1 (da)
DK (1) DK2066695T3 (da)
EA (1) EA015916B1 (da)
ES (1) ES2404941T3 (da)
HR (1) HRP20130320T1 (da)
IL (1) IL196806A0 (da)
MX (1) MX2009002470A (da)
NO (1) NO20091264L (da)
PL (1) PL2066695T3 (da)
PT (1) PT2066695E (da)
RS (1) RS52787B (da)
SI (1) SI2066695T1 (da)
UA (1) UA98308C2 (da)
WO (1) WO2008030706A2 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533464T3 (es) 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
SG187867A1 (en) 2010-08-16 2013-03-28 Amgen Inc Antibodies that bind myostatin, compositions and methods
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
PT2780368T (pt) 2011-11-14 2018-03-22 Regeneron Pharma Composições e métodos para aumentar a massa muscular e a força muscular antagonizando especificamente gdf8 e/ou activina a
FR2982860B1 (fr) * 2011-11-18 2015-07-10 Ass Fr Contre Les Myopathies Utilisation de la fibromoduline et du lumican pour augmenter la masse musculaire
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
BR112015001955A2 (pt) 2012-08-24 2017-11-07 Chugai Pharmaceutical Co Ltd variante de região fc específica de fcgamariib
SI3835310T1 (sl) 2012-09-13 2024-07-31 Bristol-Myers Squibb Company Proteini skafold domene na osnovi fibronektina, ki se vežejo na miostatin
JP6598680B2 (ja) 2013-04-02 2019-10-30 中外製薬株式会社 Ｆｃ領域改変体
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3100056A2 (en) 2014-01-27 2016-12-07 Novartis AG Biomarkers predictive of muscle atrophy, method and use
CA3005158A1 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
RU2708170C2 (ru) 2014-11-24 2019-12-04 Сомалоджик, Инк. Соединения нуклеиновой кислоты для связывания ростового фактора дифференцировки 11
EP4600372A3 (en) 2014-12-19 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016120647A2 (en) 2015-01-30 2016-08-04 Debreceni Egyetem Muscle regeneration
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
WO2016130414A1 (en) * 2015-02-09 2016-08-18 Somalogic, Inc. Nucleic acid compounds for binding growth differentiation factor 8
MA49661A (fr) 2015-04-15 2020-06-03 Regeneron Pharma Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
HU230620B1 (hu) 2015-05-14 2017-04-28 ALU-ÖNTŐ Fémöntő és Fémmegmunkáló Ipari Eljárás vékonyfalú, tagolt, részletgazdag alumínium öntvények homokformázásos technológiával, gravitációs öntéssel történő előállítására
TWI868415B (zh) * 2015-12-18 2025-01-01 日商中外製藥股份有限公司 抗肌抑素抗體、含變異fc區之多肽及使用方法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3400240A2 (en) 2016-01-08 2018-11-14 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
KR102102734B1 (ko) 2016-08-05 2020-04-22 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
GB201620119D0 (en) * 2016-11-29 2017-01-11 Pharmafox Therapeutics Ag Compounds
EP4218817A3 (en) * 2017-01-06 2023-09-06 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
IL276921B2 (en) 2018-03-01 2025-12-01 Regeneron Pharma Methods for altering body composition
CA3094400A1 (en) 2018-04-06 2019-10-10 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
WO2020131910A1 (en) 2018-12-18 2020-06-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a
EP4590698A1 (en) 2022-09-21 2025-07-30 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
WO2024138076A1 (en) 2022-12-22 2024-06-27 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US5827733A (en) 1993-03-19 1998-10-27 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 (GDF-8) and polynucleotides encoding same
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
EP1770161A3 (en) 1993-05-12 2008-04-23 Genetics Institute, LLC BMP-11 compositions
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
DK0776337T3 (da) 1994-07-08 2005-12-12 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-11
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
WO1999024057A2 (en) 1997-11-07 1999-05-20 Genetics Inst Neuronal uses of bmp-11
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
WO1999040181A1 (en) 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6368597B1 (en) 1998-05-06 2002-04-09 Matamorphix, Inc. Methods of treating diabetes
EP1147413B1 (en) 1999-01-21 2006-04-05 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
ATE461275T1 (de) 2002-09-16 2010-04-15 Univ Johns Hopkins Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
EA009056B1 (ru) 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
PE20090046A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
CA2551877A1 (en) 2003-12-31 2005-07-21 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
KR20060133049A (ko) * 2004-03-23 2006-12-22 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
CA2601667A1 (en) 2005-03-23 2006-09-28 Wyeth Detection of gdf-8 modulating agents
CN101272802A (zh) 2005-04-25 2008-09-24 辉瑞大药厂 肌肉生长抑制素的抗体
WO2006128190A2 (en) 2005-05-27 2006-11-30 The Regents Of The University Of California Compositions and methods for treatment of neural disorders using transforming growth factor-beta superfamily proteins and their antagonists
WO2007024535A2 (en) 2005-08-19 2007-03-01 Wyeth Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
ES2533464T3 (es) 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
MX2008007324A (es) 2005-12-06 2009-03-04 Amgen Inc Usos de antagonistas de miostatina.
US20070190056A1 (en) 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途

Also Published As

Publication number Publication date
WO2008030706A2 (en) 2008-03-13
PT2066695E (pt) 2013-05-23
KR101123531B1 (ko) 2012-04-20
RS52787B (sr) 2013-10-31
PL2066695T3 (pl) 2013-08-30
EA015916B1 (ru) 2011-12-30
JP5058261B2 (ja) 2012-10-24
SI2066695T1 (sl) 2013-05-31
CN101511871A (zh) 2009-08-19
US20100166764A1 (en) 2010-07-01
BRPI0716249A2 (pt) 2013-09-03
EP2066695A2 (en) 2009-06-10
UA98308C2 (en) 2012-05-10
CN101511871B (zh) 2012-07-18
KR20090039821A (ko) 2009-04-22
WO2008030706A3 (en) 2008-05-02
AU2007292555B2 (en) 2012-05-31
NO20091264L (no) 2009-04-02
ES2404941T3 (es) 2013-05-29
EA200970251A1 (ru) 2009-08-28
IL196806A0 (en) 2011-08-01
AU2007292555A1 (en) 2008-03-13
EP2066695B1 (en) 2013-03-27
US8063188B2 (en) 2011-11-22
CA2661836A1 (en) 2008-03-13
MX2009002470A (es) 2009-03-20
HK1133018A1 (en) 2010-03-12
HRP20130320T1 (en) 2013-05-31
JP2010502633A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
DK2066695T3 (da) Anti-myostatin-antistoffer
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
IL269201A (en) Glycosylated antibodies
DK2059533T3 (da) Multispecifikke antistoffer
NO344963B1 (no) Humanisert antistoff
DK2131860T3 (da) Anti-sclerostin-antistoffer
BRPI0819165A2 (pt) Anticorpos anti-vegf
PT2195026E (pt) Anticorpos anti-esclerostina
DK2046826T3 (da) Exendin-fusionsproteiner
CR10161A (es) Inmunoglobulinas
HUE038501T2 (hu) Antitest készítmények
IL212175B (en) Muc1* antibodies
DK3118221T3 (da) Proteiner
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
EP2215246A4 (en) PROTEIN SCAFFOLDS
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0820073A2 (pt) Anticorpos anti-axl
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
AT504580A3 (de) Scan-einrichtung
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0817427A2 (pt) Anticorpo anti-bst2